Beyondspring Inc (BYSI) Stock AnalysisBYSIStock AnalysisBeyondspring Inc

BeyondSpring Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. It also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Beyondspring Inc is not a good buy right now due to its current price of 0.6654, a 5-day change of -7.60%, and an RSI of 32.713 indicating oversold conditions. The company has reported consistent losses, with a net income loss of -2,159,000 USD in Q1 2026 and a forward P/E of 10.54, which suggests that the stock may still be overvalued given its financial struggles. Additionally, insider selling has increased by 343.22%, reflecting a lack of confidence from those closest to the company.

2 analysts cover BYSI: 2 rate it Buy, 0 Hold and 0 Sell.